Photodynamic Therapy for Cancer: What's Past is Prologue

Michael R. Hamblin

doi:10.1111/php.13190

Photodynamic Therapy for Cancer: What's Past is Prologue

Michael R. Hamblin

Laser Research Centre

Research output: Contribution to journal › Review article › peer-review

195 Citations (Scopus)

Abstract

Thomas J Dougherty from Roswell Park Cancer Center played a major role in the progress of photodynamic therapy (PDT) from a laboratory science into a real-world clinical therapy to treat patients with cancer. Nevertheless over the succeeding 45 years, it is fair to say that the overall progress of clinical PDT for cancer has been somewhat disappointing. The goal of this perspective article is to summarize some of the clinical trials run by various companies using photosensitizers with different structures that have been conducted for different types of cancer. While some have been successful, others have failed, and several are now ongoing. I will attempt to touch on some factors, which have influenced this checkered history and look forward to the future of clinical PDT for cancer.

Original language	English
Pages (from-to)	506-516
Number of pages	11
Journal	Photochemistry and Photobiology
Volume	96
Issue number	3
DOIs	https://doi.org/10.1111/php.13190
Publication status	Published - 1 May 2020

ASJC Scopus subject areas

Radiation
Biochemistry
Physical and Theoretical Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/php.13190

Cite this

@article{27721626a00a43faba415ca0bc0fa5d5,

title = "Photodynamic Therapy for Cancer: What's Past is Prologue",

abstract = "Thomas J Dougherty from Roswell Park Cancer Center played a major role in the progress of photodynamic therapy (PDT) from a laboratory science into a real-world clinical therapy to treat patients with cancer. Nevertheless over the succeeding 45 years, it is fair to say that the overall progress of clinical PDT for cancer has been somewhat disappointing. The goal of this perspective article is to summarize some of the clinical trials run by various companies using photosensitizers with different structures that have been conducted for different types of cancer. While some have been successful, others have failed, and several are now ongoing. I will attempt to touch on some factors, which have influenced this checkered history and look forward to the future of clinical PDT for cancer.",

author = "Hamblin, {Michael R.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Society for Photobiology",

year = "2020",

month = may,

day = "1",

doi = "10.1111/php.13190",

language = "English",

volume = "96",

pages = "506--516",

journal = "Photochemistry and Photobiology",

issn = "0031-8655",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Photodynamic Therapy for Cancer

T2 - What's Past is Prologue

AU - Hamblin, Michael R.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Thomas J Dougherty from Roswell Park Cancer Center played a major role in the progress of photodynamic therapy (PDT) from a laboratory science into a real-world clinical therapy to treat patients with cancer. Nevertheless over the succeeding 45 years, it is fair to say that the overall progress of clinical PDT for cancer has been somewhat disappointing. The goal of this perspective article is to summarize some of the clinical trials run by various companies using photosensitizers with different structures that have been conducted for different types of cancer. While some have been successful, others have failed, and several are now ongoing. I will attempt to touch on some factors, which have influenced this checkered history and look forward to the future of clinical PDT for cancer.

AB - Thomas J Dougherty from Roswell Park Cancer Center played a major role in the progress of photodynamic therapy (PDT) from a laboratory science into a real-world clinical therapy to treat patients with cancer. Nevertheless over the succeeding 45 years, it is fair to say that the overall progress of clinical PDT for cancer has been somewhat disappointing. The goal of this perspective article is to summarize some of the clinical trials run by various companies using photosensitizers with different structures that have been conducted for different types of cancer. While some have been successful, others have failed, and several are now ongoing. I will attempt to touch on some factors, which have influenced this checkered history and look forward to the future of clinical PDT for cancer.

UR - http://www.scopus.com/inward/record.url?scp=85078615999&partnerID=8YFLogxK

U2 - 10.1111/php.13190

DO - 10.1111/php.13190

M3 - Review article

C2 - 31820824

AN - SCOPUS:85078615999

SN - 0031-8655

VL - 96

SP - 506

EP - 516

JO - Photochemistry and Photobiology

JF - Photochemistry and Photobiology

IS - 3

ER -

Photodynamic Therapy for Cancer: What's Past is Prologue

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this